logo
STOKKE DEBUTS YOGA, INNOVATIVE DUAL MOTION BABY BOUNCER AND SWING

STOKKE DEBUTS YOGA, INNOVATIVE DUAL MOTION BABY BOUNCER AND SWING

Stokke, the renowned Scandinavian brand behind the Tripp Trapp®, announces the launch of the Stokke Yoga, setting a new standard for baby bouncers and swings. Offering two motions in one unique design, the Stokke® Yoga™ is the first of its kind, featuring innovative dual-motion technology with motor-free bouncing and swinging movements, initiated by the baby or caregiver.
Developed with input from physiotherapists, the Yoga is designed to soothe, stimulate, and support development. The unique movement is patent-pending and made to trigger the vestibular system through swinging, bouncing, and rocking, giving babies the stimulation they naturally crave. Through these motions, the Yoga can improve balance, soothe little ones, and support essential developmental milestones like posture, sitting, crawling, and walking.
Made with modern families in mind, the Yoga™ features breathable mesh fabric with a soft cotton top and polyester underneath, ensuring comfort while releasing heat to keep babies cool. It includes three recline positions for different developmental stages, a removable newborn cushion for infants up to 20 lbs, and a thoughtful ergonomic design to support even the tiniest newborns. The legs are crafted from FSC-certified European beechwood, the same durable material used for the iconic Tripp Trapp® chair.
With the Yoga's unique combination of bouncing and swinging, it mimics the soothing rhythm of being cradled in a parent's arms, offering both comfort and developmental benefits. 'Parents intuitively use movements that imitate patterns of nature, like waves or the motions of the womb, to soothe or stimulate their newborns,' shares Designer Bianca Hanauer. 'Stokke® Yoga™ mimics these natural movements, which also helps infants slowly learn how to swing or bounce themselves.'
Assembly is quick and tool free, simply snap in the pole and adjust it to the ideal position. Disassembly is just as easy, with the bouncer folding flat for convenient storage or travel.
The Stokke® Yoga™ is available now on Stokke's website. For more on Stokke and their product offerings, visit www.stokke.com.
ABOUT STOKKE
Founded in Ålesund in 1932, Stokke is a proud Norwegian company globally recognized for best-in-class solutions in high chairs, strollers, nurseries, baby carriers, and more. Merging Scandinavian design with innovation, Stokke creates premium products that encourage healthy child development and nurture family bonding. Their mission is simple: to support parents in raising confident kids for a better world. With connection, safety, and exploration as our foundation, Stokke transforms this promise into action by making innovative products that promote parent-child closeness, exemplified by the iconic Tripp Trapp® chair. Their commitment to sustainability drives the use of durable, high-quality materials, vital for crafting long-lasting products with grow-with-your-child functionality and timeless design, so we can move towards a more sustainable future.
Media Contact
5W Public Relations

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Yahoo

time28 minutes ago

  • Yahoo

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.

Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Presents New Data on the Benefits of ALYFTREK

Yahoo

time28 minutes ago

  • Yahoo

Vertex Presents New Data on the Benefits of ALYFTREK

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Establishment Labs Hosting Investor Day on June 12
Establishment Labs Hosting Investor Day on June 12

Yahoo

timean hour ago

  • Yahoo

Establishment Labs Hosting Investor Day on June 12

NEW YORK, June 11, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store